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Abstract 
 
Skeletal muscle repair following Plantar nerve relocation on an 
extracellular matrix seeded with mesenchymal stem cells in a 
PEGylated fibrin gel as a treatment model for volumetric muscle loss. 
 
Adriana Jocelyn Da Costa, M.S. Kin 
The University of Texas at Austin, 2014 
 
Supervisor:  Roger P. Farrar 
 
The toll skeletal muscle injury, resulting in significant muscle mass loss, has on 
the patient reaches far more than physical and emotional, as the tolls are financial as well. 
Approximately more than 3 billion dollars is spent on the initial medical costs and on 
subsequent disability benefits, following a volumetric muscle loss. Skeletal muscle has a 
robust capacity for self-repair; this propensity for repair is hindered when skeletal muscle 
loss is larger than 20% of the total mass of the muscle. Previous work in our lab, has 
shown functional and morphological improvements following the cellular therapy, with 
mesenchymal stem cells (MSC), as well as with nerve relocation to the extracellular 
matrix (ECM). To further observe the regenerative properties of the above treatments, a 
defect weighing approximately 307 ± 3.7 mg wet weight and measuring approximately 
1x 1cm² was removed from the lateral gastrocnemius (LGAS) of male Sprague Dawley 
rats. Additionally, the medial branch of the plantar nerve was then relocated and 
implanted to the middle of the ECM. Seven days post injury bone-marrow derived 
 vii 
mesenchymal stem cells were injected directly into the implant using a PEGylated Fibrin 
hydrogel (PEG). Following 56 days of recovery, partial functional restoration was 
observed in the LGAS ECM seeded with MSC and implanted with the plantar nerve. The 
LGAS produced 86.3 ± 5.8% of the contralateral LGAS, a value that was significantly 
higher than ECM implantation alone (p <.05). The implanted ECM seeded with MSC and 
implanted with the plantar nerve showed significant increases in blood vessel density and 
myofiber content (p <.05). The data suggest that a volumetric injury can be repaired by 
neurotization of an implanted muscle-derived ECM seeded with MSCs.   
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 1 
INTRODUCTION 
  
Degenerative diseases, surgical ablations, traumatic motor vehicle accidents, 
traumatic injuries caused by improvised explosive devices (IEDs), and gunshot wounds 
in both civilian and military populations often result in severe muscle loss. In 2014 alone, 
the department of defense has appropriated 30 million dollars to support research focused 
on restoring function of orthopedic injuries sustained by military personal in combat. The 
research done for injuries in military populations can also translate to civilian 
populations. The aforementioned injuries, often characterized by severe soft tissue 
damage, significant loss in tissue mass and functional deficits fall under injuries known 
as volumetric muscle loss (VML) (Grogan and Hsu, 2011). Despite significant losses in 
mass and function, as well as physical and aesthetic discomfort to the patient, there is no 
clinical standard for VML, and therapeutic advances have been limited to the use of 
carbon-fiber braces and autologous functional free muscle transfer (Grogan and Hsu, 
2011, Fan et al., 2008, Li et al., 2013). Clinical treatments are limited to injuries 
occurring below the knee or in other similar extremeties, apply only to small areas of 
tissue, and risk donor site morbidity and loss of function (Grogan and Hsu, 2011, Tu et 
al. 2008, Fan et al., 2008). Another caveat of free muscle transfer is that the donor 
muscle must meet special requirements in length, fiber characteristics, point of origin and 
insertion, as well as meet certain specification in vascular and neural supply to be 
considered for donation. Characteristics that limit possible donor muscles to a few type 1 
muscles (Zuker and Manktelow, 2007). Free muscle transfers have been met with varying 
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results. Roughly four-fifths of patients receiving a free muscle transfer are able to regain 
full elbow flexion, yet some experience difficulty in regaining functional strength when 
flexion is tested with a 3lb weight (Seal and Stevanovich, 2011, Zuker and Manktelow, 
2007).  These varying results in functional measures make the search for clinical 
alternatives imperative to the treatment of VML.  
Skeletal muscle, composed of myofibers and connective tissue, heals through an 
intrinsic repair process in which a normally quiescent population of cells, known as 
satellite cells, becomes activated upon injury. These cells which normally reside under 
the basal lamina proliferate, then differentiate into myoblasts, and subsequently fuse 
together to form myotubes (Jarvinen et al., 2005). The process of self repair becomes 
hindered when the area between the ruptured stumps is insurmountable, leaving the 
remaining muscle fibers unable to fuse together, as well as due to the formation of 
extraneous scar tissue between the ruptured stumps (Huard et al. 2002). As is common in 
VML injuries, these problems in repair often leave the area devoid of muscle fibers or 
leave the tissue with a sizeable gap between muscle fibers (Merritt et al, 2010, Terada et 
al, 2001). Thus, a biocompatible material to bridge the gap between myofibers is 
paramount to the treatment of VML injury.  
Orthopedic surgeons and civilian medical, as well as military personnel are faced 
with the task of repairing not only muscle tissue but collagen, nerve and vascular tissue 
after a VML injury. These challenges have led to research into biocompatible materials 
that might aid in reconnecting the remaining muscle fibers, diminish the need for 
autologous tissue, multiple surgical procedures, as well as produce an environment 
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conductive to angiogenesis and neurogenesis within the defect. Research in tissue 
engineering has looked at several autologous, non autologous/acellular grafts, as well as 
naturally based materials, and synthetic materials, as scaffolds for regeneration of both 
muscle and nerves from both the central nervous system and peripheral nervous system 
(Schmidt and Baier Leach, 2003).   Hydrogels, collagen and laminin structures, polymer 
matrices and decellularized tissues are being researched with the aim of improving 
musculature, vasculature, and nerves within the matrix, as well as functional capacity of 
the tissue (Madaghiele et al, 2007, Li et al., 2007). Porcine small intestinal submucosa 
(SIS) implantation as treatment for VML has shown promising results in regeneration in 
animal studies. However many studies using SIS have looked only at abdominal wall 
models of VML injury and few have focused on the use of SIS in the treatment of VML 
in load bearing muscles. Initial results have shown impaired regeneration, non functional 
muscle, bone and cartilage in the treatment of the vastus lateralis muscle following 
treatment with SIS (Turner et al., 2012). A clinical case study looked at SIS in the repair 
of a quadriceps femoris muscle and found soft tissue development within the muscle 
using CT scan, as well as improvement in isokinetic function following 36 weeks of 
recovery (Mase et al., 2010). The limitation in this study is that Biodex measures only the 
combined contribution of all muscles in the quadriceps, thus making it difficult to 
determine if the improved effects seen are isolated to an improvement in the vastus 
lateralis or a compensatory effect of the surrounding muscles. Although an improvement 
in isokinetic function and subjective self-assessment is shown, the data shows that 
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compared to the contralateral leg, function remains well below normal levels, showing a 
need for continued research in viable methods to increase and restore function.  
Successful treatment utilizing scaffolds requires scaffolds to balance mechanical 
function, provide a modulus within (.4-350MPa), and deliver biofactors, which play a 
role in bone, soft tissue, and neural regeneration (Hollister, 2005). Research has 
suggested that using naturally based scaffolds in homologous sites aids in regeneration 
due to site- specific extracellular matrix (ECM) composition and structure, specifically 
the axially oriented pores (Wolf et al., 2012, Madaghiele et al., 2007).  The innate 
structural characteristics of homologous ECM have made it an attractive option in the 
treatment of VML injuries.  Extracellular matrices produced through the process of 
decellularization aid in remodeling of tissue through their recruitment of various cells to 
the site of injury; including inflammatory cells, stem and progenitor cells. The 
extracellular matrix three dimensional structure and array of structural and functional 
proteins help to dictate the topography and relocalization of synapses, blood vessels, and 
cells in the tissue (Singhal and Martin, 2011, Wolf et al., 2011, Badylak, S.F, 2007, 
Valentin et al, 2006). Additionally, studies have shown that ECMs containing fibronectin 
display enhanced motoneuron outgrowth, while on the other hand, laminin aids in the 
recruitment of Schwann cells (Gonzalez-Perez et al., 2013).  While the innate 
characteristics of homologous ECM make it a viable option for treatment of VML, 
studies within our laboratory have shown limitations in regeneration in the middle 
fraction of the ECM, as well as significant deficits in function, when an ECM is 
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implanted alone (Merritt et al, 2010a, Merritt et al, 2010b). A combination of treatments 
is likely a solution for the impairments seen in treatment with ECM only.  
Great importance has been placed on the use of bone marrow derived 
mesenchymal stem cells (BMSC) in the field of regenerative medicine due to the ease of 
isolation, expansion potential, differentiation ability into multiple cell lines, and 
migratory pattern to sites of injury (Ripoll and Bunnell, 2009, Pittenger and Martin, 
2004). Furthermore, BMSCs can be autologously obtained which reduces the likelihood 
of eliciting an immune response; their lack of immunogenicity makes them an ideal 
candidate for regenerative treatment even when allogenically obtained (Pittenger and 
Martin, 2004).  Various clinical and animal studies have looked at the role of BMSCs 
(both whole cell and cell extract) in myocardial infarction; these studies have shown 
improvements in function, following intravenous infusion despite embolism in the lung 
(Lee et al., 2009, Martin et al., 1999, Yeghiazarians et al., 2009). Additionally, BMSCs 
were found to express myogenic potential, as they have been found to express several 
myogenic transcription factors including pax 7, myoD, myogenin, myf-5 and myogenic 
proteins following transplantation (Dezawa et al., 2005, Pittenger and Martin, 2004, 
LaBarge and Blau, 2002). Although the exact methods by which BMSC contributes to 
muscle repair are unknown and debated, various studies have shown repair through 
repopulation of the satellite cell niche, varying levels of engraftment after culture on 
plastic or PEGylated fibrin hydrogel (PEG) wells, fusion, or through an 
autocrine/paracrine fashion via release of growth factors and chemokines that alter the 
environment (Prockop, 2003, Labarge and Blau, 2002, Gilbert et al., 2010, Dezawa et al, 
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2005, Palermo et al., 2005, Merritt et al., 2010a, Collins et al, 2005, Prockop, 2009, 
Gimbel et al., 2009).  Bone marrow derived stem cells have been shown within our lab to 
aid in regeneration by increasing myofiber content, size, blood vessel density and 
function following 42 day and 56 day recovery post injury (Merscham et al., 2012 
(unpublished), Sarathy et al, 2011 (unpublished), Tierney et al, 2009 (unpublished), 
Merritt et al, 2010a). Additionally, BMSC are shown to express an array of genes for all 
three germ layers, a characteristic important for treatment of VML injuries as nerve 
regeneration and vasculogenesis are important to the long term survival of muscle fibers 
(Woodbury et al., 2002). The ability of BMSC to differentiate into various tissues makes 
the topic of delivery to the injury site of importance.  
 In the past multiple bolus injections into the site of injury were the preferred 
method of growth factor and BMSC delivery, recently, however, tissue engineering has 
developed a synthetic material, polyethelene glycol conjugated to fibrin, PEGylated 
Fibrin (PEG-fib), which releases the covalently bound growth factors and BMSC in a 
temporally and spatially controlled manner from a single injection (Schmidt and Baeir 
Leach, 2003). PEGylated Fibrin gels deliver contents into the site of injury as the 
polymer and covalent bonds binding the bioactive factors are degraded. Previous studies 
using PEG-fib as a bioactive factor delivery agent, in myocardial infarction models, 
showed improved left ventricular function following treatment (Zhang et al., 2007, Zhang 
et al., 2008). Additionally a subsequent study looking at the role of IGF release into 
tourniquet induced ischemia/reperfusion (I/R) found that while most of the IGF was 
released within the first 24 hr after injection, IGF continued to be released at 
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physiologically relevant quantities 96 hrs post injection; an effect that significantly 
improved functional and morphological recovery of the lateral gastrocnemius (LGAS) 
(Hammers et al., 2011). The role PEG-fib has in bioactive factor delivery makes it an 
attractive option for VML treatment.  
 Of great importance is the role of motoneurons in the regeneration and long term 
survival of muscle fibers. Without continued stimulation muscle fibers initially recover 
but cannot sustain regeneration and functional impairments arise (Borisov et al., 2001, 
Borisov et al, 2005). The morphology of muscle is directly influenced by activation and 
innervation of the nerve as seen by cross-innervation studies (Nehrer-Tairych, et al., 
2000). Neurotization of the ECM and associated myofibers is likely to enhance 
regeneration. An increase in ectopic motor endplates distal to native end plates is seen 
due to neurotization of distal zones, indicating the importance of implant location in end 
plate formation and reinnervation. This study however did not measure functional output 
to analyze differences in location and resulting end plate morphology (Payne and 
Brushart, 1997). Neural growth factors and brain derived growth factors, known as 
neurotrophins, are secreted by peripheral nerves and aid the regulation of axonal growth, 
survival and death. Studies in which neurotrophic KO mice are used, exhibit decreased 
muscle development and function, or postnatal lethality, indicating an important 
physiological role of neurotrophic factors in muscle regulation (Clow and Jasmin, 2010). 
Nerve growth factor (NGF) has been shown to be expressed in regenerating myofibers 
and when engineered to be expressed in stem cells dystrophic mice show improvements 
in regeneration. On the other hand, brain derived neurotrophic factor (BDNF) plays a key 
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role in satellite cell function and muscle regeneration (Clow and Jasmin, 2010, Lavasani 
et al., 2006). The positive effect seen with neurotization of muscle tissue alone, or in 
concert with other bioactive factors, on muscle repair make a strong case for the use of a 
combined treatment as a therapeutic modality for VML injury.  
 Therefore, this study aimed to investigate the effects of a combined treatment in 
the functional and morphological recovery of the lateral gastrocnemius muscle, 56 days 
post VML injury using plantar nerve relocation on an extracellular matrix seeded with 
mesenchymal stem cells in a PEGylated fibrin gel. 
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REVIEW OF LITERATURE 
Skeletal Muscle Overview 
 Skeletal muscle, made up of individual multinucleated myofibers that bundle 
together and are surrounded by the endomysium, perimysium, and lastly the epimysium, 
constitutes approximately 45% of one’s body weight in the normal population and is of 
great importance to locomotion (Huard et al., 2002, Juhas and Bursac, 2013). It is 
composed of many structural and functional proteins and within its framework, it 
contains vascular and neuronal processes that aid in the muscle’s functional propensity. 
Its capacity for regeneration and self repair has been extensively studied. Skeletal muscle 
injuries can occur due to three direct traumatic causes: contusion, strain, and laceration or 
indirect causes such ischemia and neurodegeneration (Jarvinen et al., 2005, Huard et al., 
2002). Unlike other tissues in the body, skeletal muscle has a great propensity for self 
repair, even with aging, unless involved in traumatic injuries. Muscle begins regeneration 
promptly following severe soft tissue damage but depending on the severity of injury can 
be hindered due to scar tissue deposition within the site of injury. The process of self 
repair in skeletal muscle can be broken down into three distinct phases.  
 
Destruction phase  
 The destruction phase following skeletal muscle injuries is characterized by 
lesions/rupture of the ECM, sarcoplasmic reticulum, and its associated myofibers, this 
damage then results in necrosis of those injured myofibers (Jarvinen et al., 2005). The 
ruptures associated with injury cause an influx of calcium into the tissue which then leads 
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to subsequent activation of proteases. Furthermore, necrosis is characterized by two 
distinct steps: a rapid onset in which plasmalemmal and myonuclear losses are seen, and 
then a gradual necrosis that leads to contractile material and cellular organelle loss 
(Karpati and Molnar, 2008). However, in order to prevent the propagation of necrosis 
along the entire muscle fiber, skeletal muscle forms a contraction band that acts as a 
sealant of the plasma membrane through lysosomal vesicle deposits, in order to allow the 
muscle fiber to repair the plasma membrane and its associated defect area (Jarvinen et al., 
2005, Jarvinen et al., 2007, Jarvinen et al., 2008). In addition to the injury suffered by the 
plasma membrane of skeletal muscle, ruptures also occur in the associated blood vessels 
which lead to the release and leukocytes to the injured area. The first inflammatory cells 
to respond are a type of phagocitotic white blood cell, known as neutrophils, which clear 
the site of injury from necrotic tissue and debris through oxidative and proteolytic 
modification (Tidball, 2005). A second type of phagocitotic white blood cell, known as a 
macrophage, then follows to continue clearance of debris. Tissue macrophages and 
fibroblasts within the injury then become activated, and begin the release of chemokines, 
such as TNFα and IL-6, as well as MCP-1 which attract circulating inflammatory cells 
(Juhas and Bursac, 2013, Jarvinen et al., 2005, Jarvinen et al, 2008, Schiaffano and 
Partridge, 2008, Tidball, 2005, Chazaud et al., 2008, Charge and Rudnicki, 2004). Once 
inflammation and necrosis removal has slowed down the macrophage profile within the 
muscle is said to change from M1 phagocitotic macrophages to anti-inflammatory M2 
within 24 -48 hrs post injury (Rigamonti et al., 2014, Arnold et al., 2007, Chazaud et al., 
2008). M2 macrophages play a role in the decrease of inflammation and switching the 
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environment towards one conductive to regeneration through their secretion of TGF-β, 
IGF1, and IL-10 (Rigamonti et al., 2014, Tidball, 2004). Despite the differences in 
secretion and function between the two populations of macrophages, ultimately both 
populations act on satellite cells to first activate and proliferate, and then to differentiate 
(Rigamonti et al., 2014, Tidball, 2005, Jarvinen et al., 2005). Tissue necrosis and 
inflammation play a key role in muscle regeneration due to their role in chemokine 
release and without them regeneration is hindered.  
 
Repair phase: 
 Although thought to be a distinct phase, the repair phase begins during the 
degeneration phase due the effects macrophages have on satellite cell activation, 
proliferation, and differentiation. The repair phase is characterized by two simultaneous 
processes: muscle fiber regeneration and scar tissue formation (Jarvinen et al., 2005). 
Muscle fiber regeneration begins with the activation, proliferation, migration to the site of 
injury, and then differentiation of pax 7+ satellite cells into myoblasts, through 
expression of MyoD (Juhas and Bursac, 2013, Wang and Rudnicki, 2012, Charge et al., 
2004, Collins and Partridge, 2005). Activation of satellite cells is characterized by 
nuclear enlargement, nucleus to cytoplasmic mass increases, and upregulation of DNA 
synthesis (reviewed in Carlson and Faulkner, 1983). Studies looking at satellite cell 
activation have shown that the autocrine splice variant produced by muscle, mechano 
growth factor, is responsible for the early activation of satellite cells while insulin growth 
factor is responsible for the maintained activation and proliferation, as IGF-1 expression 
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peaks at 11 days post injury (Hill et al., 2003). Once committed to a myogenic lineage, 
satellite cells express myogenin, continue myoblast proliferation, followed by fusion to 
damaged tissue or each other. Satellite cell engraftment into muscle tissue has been 
extensively studied in many animal models and it has been shown that ablating the 
satellite population of a mouse and implanting β-gal satellite cells generates myofibers in 
which over 50% of the population are β-gal + (Collins et al., 2005). Additionally, it has 
been shown that as few as 7 satellite cells can produce more than 10 times the amount of 
myofibers per satellite cell (Collins et al., 2005). With age the capacity for self renewal 
and repair of skeletal muscle diminishes, due in part to impaired Notch and Delta 
signaling. Parabiosis studies with old and young mice have shown the importance of 
satellite cell activation through their environment. In these studies old mice matched with 
young environments saw enhanced muscle regeneration in part due to an upregulation of 
Delta in the old mice (Conboy et al., 2005). These studies show the significance in the 
role that niche regulation plays on satellite cell activation and the subsequent role that 
these cells have on regeneration. 
 While satellite cells are the primary contributors to new nuclei in the muscle, 
different populations of cells have been shown to also play a role in the regeneration of 
skeletal muscle. Notable are the resident muscle-derived stem cells and the bone marrow 
stem cells (Charge, 2004, Juhas and Bursac, 2013). These cells travel to the site of injury 
from locations distant to the injury and muscle and either directly contribute to 
regeneration through myonuclei donation or through secretion of growth factors that alter 
surrounding cells and contribute to a changing niche environment (Quintero et al., 2009, 
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Sun et al., 2009, Tedesco et al., 2010). The exact mechanism by which they contribute to 
muscle regeneration is still relatively unknown, but it is hypothesized that these cells may 
contribute to the repopulation of the satellite cell pool (Kuang et al., 2008, Usas and 
Huard, 2007). Additionally, the tolerance displayed by muscle derived cells to 
manipulation ex-vivo, as well as their multipotency, make them viable options for 
regenerative purposes (Usas and Huard, 2007, Lavasani et al., 2006). Thanks to cellular 
contribution by these groups of stem cells the repair phase is characterized by the 
regeneration of myofiber, endothelial, and nerve tissue.  
 Following injury, ruptured fibers are filled with a hematoma and blood-derived 
cells infiltrate the site of injury, such as fibrin and fibronectin which form granulation 
tissue (Jarvinen et al., 2005). This tissue acts as a way to bridge the gap between the 
myofiber stumps and to provide tensile strength within the tissue while the fibroblasts 
restore the ECM integrity (Jarvinen et al., 2005). Unfortunately, if injury to skeletal 
muscle is significantly severe scar tissue formation can hinder regeneration.  
  
Remodeling Phase 
 In the remodeling phase after injury, maturation of myofibers are witnessed by the 
migration of nuclei from a central position to the periphery. This transition causes the 
nuclei to then form attachments to the extracellular matrix. Maturation of myofibers and 
scar tissue remodeling continues via myofiber protrusion through the scar until function 
is restored (Jarvinen et al., 2005, Kaairiainen et al., 2000). This remodeling phase is 
hindered when damage is significant and the fibrotic scar tissue is too large to overcome, 
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an effect that is largely seen in trauma related injuries, such as VML injury. The resulting 
tissue is then left devoid of myofibers, nerve, and expresses large functional deficits. In 
this study we examined neurotization and stem cell administration as therapeutic 
strategies for VML injury, to counteract the deficits seen in regeneration with in this 
injury model.  
 
Skeletal Muscle Trauma 
 Penetrating traumatic lesions to the extremities comprise a large population of 
injuries in the battlefield by military personnel, those going through surgical ablation and 
motor vehicle accidents within the civilian population. In the case of battlefield injuries, 
over half of the injuries in Operation Iraqi freedom and Operation Enduring Freedom 
were skeletal muscle injuries (Owens et al., 2006). Injury is quite extensive and 
comprises damage to the skeletal muscle, bone, nerve, and vascular system within the 
tissue. Primary care to the injuries focuses on bone repair and prevention of infection, 
often leaving the tissue untreated. Patients incur significant muscle loss, known as 
volumetric muscle loss, lack of adequate vascularization, and improper nerve stimulation 
which result in significant functional deficits, as well as cosmetic deformities, and 
associated mental distress. Volumetric muscle loss injuries display increased scar tissue 
deposition and reduced regenerative capabilities. If the muscle is left untreated, 
myofibers are unable to bridge the gap by their own repair process and a major deficit 
within the tissue is observed, which is then followed by deposition of dense scar tissue 
rendering it impossible for penetration by myofibers and blood vessels (Merritt et al., 
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2010, Terada et al., 2002). Limb salvage for VML injuries does not restore function in 
the tissue and currently clinical treatments use function free muscle transplants, which 
risk donor site morbidity and infection, and bracing to further treat the injury (Grogan 
and Hsu, 2011). In a study that looked at deployment following limb salvage, the authors 
reported four patients requesting late amputation due to debilitating functional loss 
(Patzkowski et al., 2012). Furthermore, a study looking at medical costs for treatment of 
VML injuries by the department of defense estimates over a half a billion dollars for 
initial hospital treatment and close to two billion dollars in disability benefits (Masani et 
al., 2009). Therefore, it is imperative that treatments should focus on enhancing myofiber 
repair/regeneration within an appropriate scaffold which is conductive to increased 
regeneration, in order to increase function.   
 
Extracellular Matrix as a Conduit for Regeneration 
In recent years, due to autologous tissue grafts leading to donor site morbidity and 
hindered functional regeneration, bioengineering strategies have searched for alternatives 
to increase regeneration of tissue.  Tissue engineering has looked at a number of 
nonautologous/acellular grafts, natural-based materials, and synthetic materials to aid in 
both skeletal muscle and nerve regeneration (Schmidt and Baier Leach, 2003). Xenogenic 
and synthetic materials have been attractive alternatives to tissue grafts due to their 
reproducibility, availability, and patient tissue exclusion. Despite their attractiveness in 
tissue engineering, these materials possess risk of disease transmission, elicit 
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immunogenic responses, and in certain cases, impermeable materials do not support large 
defect regeneration (Schmidt and Baier Leach, 2003, Meintjes et al., 2011). Thus focus 
should be placed on natural-based materials like the extracellular matrix for tissue 
regeneration. The extracellular matrix is a three-dimensional structure that contains 
proteins and carbohydrates and is responsible for aiding in cell proliferation, 
differentiation, and migration. The ECM is present in all tissues of the body and aids in 
function by allowing transduction of mechanical force down the ECM, provides 
structural support, and it provides the framework for tissue growth, communication, and 
cellular infiltration (Gonzalez-Perez et al., 2013, Badylak, 2007, Brown et al., 2009). 
Studies have shown pliability of the ECM to have an effect on MSC, with soft matrices 
enhancing MSC regeneration of endothelial tissue (Wingate et al., 2013).  Individual 
components of the ECM have been isolated and studied but have shown differences in 
response. Of the ECM proteins, collagen, laminin, fibronectin, and integrin have been 
extensively studied (Singhal and Martin, 2011, Gonzalez-Perez et al., 2013, Badylak, 
2008, Hinds et al., 2011). Laminin and nerve growth factor seeded on an agarose 
hydrogel, show dorsal root ganglia neurite extension comparable to collagen matrices 
experiments (Yu et al., 1999). Collagen and fibronectin composition of hydrogels have 
shown to increase contractility of tissue (Hinds et al., 2011) and Schwann cell 
proliferation (Armstrong et al., 2007). On the other hand, tissue exhibiting deficiencies in 
any of these components exhibit improper function and formation, notably those with 
laminin β2 deficiencies show decreased Schwann cell migration, while those lacking 
integrin β1 lack innervation by the motor neuron and show impaired myoblast fusion 
 17 
(Singhal and Martin, 2011, Schwander et al., 2003, Schwander et al., 2004). Additionally, 
diseases in which ECM proteins are altered or defective show increased muscle cycling 
between regenerative and degenerative states. All together this contributes to the need for 
complete ECM use for proper tissue regeneration.  
Currently there are many commercially available scaffolds for use from various 
tissues including bovine, porcine, and human (Brown and Badylak, 2014, Badylak et al., 
2008). The most researched ECM for tissue regeneration is the xenogenic porcine ECM 
of the SIS and have been used in volumetric muscle loss models, as well as in the 
reconstruction of urinary tract, skin, and arteries (Badylak, 2003). The SIS scaffold is 
constructed by vacuum pressing several layers of the tissue together (Badylak, 2007). SIS 
scaffolds have been used in comparative studies and have been shown to increase cellular 
response (Wolf et al., 2012, Badylak and Gilbert, 2008). Additionally, the use of SIS in a 
clinical application to treat VML has shown an increase in function following reparative 
treatment (Mase et al., 2010). Of great importance in regenerative therapies have been 
studies which have shown that non cross-linked ECMs have increased 
neovascularization, cellular infiltration and substantial tissue remodeling (Wolf et al., 
2012, Badylak, 2004). However, tissue ECM must first be decellularized for implantation 
as cellular remnants produce an immunogenic response characterized largely by type one 
macrophages, a characteristic that greatly reduces regeneration capacity of the tissue. 
Studies have shown that acellular grafts are more conducive to regeneration, in part due 
to the recruitment of type two macrophages through degradation, by plasminogen (Sicari 
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et al., 2014, Brown et al., 2009), and subsequent remodeling, which leads to 
chemoattractant release and recruitment of progenitor cells to the tissue (Badylak et al., 
2009, Badylak and Gilbert, 2008, Badylak, 2008, Badylak et al., 2001). Furthermore, 
comparative studies have shown increased perivascular stem cell growth in muscle 
derived ECM scaffolds compared to SIS-ECM a characteristic attributed to growth 
factors and attachment proteins specific to muscle derived ECM (Wolf et al., 2012). After 
injury, macrophages and satellite cells secrete matrixmetalloproteinase (MMP) which 
causes bound growth factors, such as vascular endothelial growth factor (VEGF) and 
hepatocyte growth factor (HGF), to be released into the environment, which in turn 
signals migration of progenitor cells to the area (Lolmede et al., 2009, Tatsumi, 2010). A 
study looking at C2C12 myoblasts seeded on decellularized, muscle derived ECM extract 
coated surfaces saw an increase in proliferation and differentiation of myoblasts (Stern et 
al., 2009) while implantation of C2C12 myoblasts into the ECM increased contractility 
following incubation in differentiation medium (Borschel et al., 2004). Thusly, tissue-
specific ECMs are emerging as an attractive alternative to xenogenic tissue in VML 
injuries due to specificity of growth factors and proteins within the ECM and their 
conduciveness to regeneration of the tissue.  
Work within our laboratory on muscle derived ECM in volumetric muscle loss 
injuries has shown promising results. Experiments have shown that implantation alone 
does not restore function; yet seeding with mesenchymal stem cells produces an increase 
in contractility of the tissue (Merritt et al., 2010). However, despite improved 
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contractility histological analysis showed an area devoid of blood vessels and myofibers. 
A subsequent unpublished study showed significant functional recovery and myofiber 
regeneration, in the previously hypoxic core, 42 days post injury following neurotization 
(Tierney et al., 2010). Another study within our lab delivered MSCs using a PEGylated 
fibrin gel 56 days post injury, in a larger defect area, showed marked improvements as 
well (Merscham-Banda et al, 2012).  Therefore, a combination of treatments is likely 
prospect for future studies of VML.  
Mesenchymal Stem Cells in Muscle Repair 
Stem cells have long been an attractive tool for cellular and regenerative 
therapies; however, recent studies have focused on isolation of stem cells from a variety 
of sources, including adult tissue. Mesenchymal stem cells, first characterized by 
Freidenstein in 1974, have been shown to give rise to osteocytes, adipocytes, and 
chondrocytes in vitro and are an attractive tool in cell therapy due to their accessibility, 
adherence in culture, and proliferative capabilities, as well as their transdifferentiative 
abilities due to spontaneous cell fusion (Pittenger et al., 1999, Keilhoff et al., 2006, 
Woodbury et al., 2002, Terada et al., 2002, Ripoll and Bunnell, 2009).  Despite their ease 
of acquisition through bone marrow aspiration, these cells have been difficult to 
characterize due to presence of intermittent surface marker presentation, such as CD 34 
during certain conditions, and the same markers in both stem populations and non stem 
populations (Pittenger et al., 1999, Pittenger and Martin, 2004). Initially, following 
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isolation the cell population is heterogenous but following multiple weeks of expansion 
the population becomes more homogenous (Pittenger and Martin, 2004, Prockop, 1997).  
Mesenchymal stem cells are an attractive treatment model for their potential 
incorporation into muscle tissue. Interestingly, following a bone marrow transplant and 
subsequent irradiation treatment of satellite cells in animal models, green fluorescent 
protein tagged (GFP+) MSCs have been shown to mobilize and occupy the satellite cell 
niche, indicating a large role in MSC repopulation of another stem cell population 
(LaBarge and Blau, 2002, Collins et al. 2005, Dezawa et al., 2005). Additionally, 
following exercise induced stress a 20 fold GFP+ increase is seen in myofibers, 
indicating incorporation of these MSC first into the satellite cell niche and then into 
myofibers. Other studies have looked at intravenous delivery of MSCs and have been met 
with promising results, indicating that circulating bone marrow cells have a large 
capacity to aid in repair of tissue as seen by parabiosis studies in which incorporation of 
MSC are seen following damage (Palermo et al., 2005). Following intravenous 
administration of MSC in irradiated mdx mice, hematopoietic cells were shown to be 
donor-derived at 5 weeks, and after 12 weeks as many as 10 percent of myofibers showed 
recovered expression of dystrophin (Gussoni et al, 1999). In a similar study CD 271+ 
MSCs were intravenously injected in canine model of Duchenne muscular dystrophy and 
saw upregulation of dystrophin, 12 weeks post treatment (Nitahara-Kasahara et al., 
2012). Intravenous injections of human mesenchymal stem cells have also shown to 
improve heart function following myocardial infarction (Yeghiazarians et al., 2009, Lee 
et al., 2009).  The cardioprotective effect witnessed in stem cell transplantation, has been 
 21 
characterized by the secretion of anti-inflammatory, TNF-α protein 6 (TSG-6), as well 
several growth factors, including vascular endothelial growth factor (VEGF), nerve 
growth factor beta (NGF-β), brain-derived neurotrophic factor (BDNF), and insulin-
growth factor (IGF) (Lee et al., 2009, Qu et al., 2007, Sadat et al, 2007). Stem cell 
therapies have also been useful in peripheral nerve repair studies in which intravenous 
injections of MSC following nerve crush injuries showed improvements in functional 
measures 7 days post treatment and maintained through 21 days. Additionally within this 
study, histological measures showed increased axonal regeneration (Matthes et al., 2013). 
Despite increased evidence of the beneficial role of MSCs in regenerative treatments, 
debate and uncertainty persists on the mechanisms for functional and morphological 
improvements following MSC treatment (Prockop et al., 2003). Taken together these 
studies show an immense potential for regenerative therapy.  
 
Stem Cell Delivery Using a PEGylated Fibrin Gel  
 Research in the field of tissue engineering has experimented with natural 
materials and synthetic materials for drug and biofactor delivery due to the short half-life 
of most growth factors. Similar to the way ECM provides a three dimensional 
environment for proliferation and differentiation, growth, and attachment of cells, 
synthetic materials such as matrigel and hydrogels are able to mimic these characteristics 
as well. Matrigel experiments for MSC delivery found both angiogenesis and 
vasculogenesis two weeks post implantation compared to matrigel only, explained by 
depleted oxygen tension in the Matrigel implant which causes and upregulation of VEGF 
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production by MSCs ( Al-Khaldi et al., 2003). Drug and biofactor delivery is being 
improved through the synthesis of biomaterials that use cytokine affinity to fibrin in order 
to contain these biofactors within the matrix. Another biofactor delivery tool is Poly-
(ethylene glycol) (PEG), a nontoxic hydrophilic polymer, that in a process called 
PEGylation, is conjugated to fibrinogen and thrombin from human plasma. Studies 
looking at the effect of these biomaterials, have found that PEG aids in the prevention of 
nerve cell rupture following spinal cord injury by sealing damaged membranes, while 
delivery of fibrin alone via subcutaneous administration stimulates capillary ingrowth 
(reviewed in Nisbet et al., 2008, reviewed in Zhang and Suggs, 2007).  Due to their 
individual effects, researchers have thus looked at the effects of combining PEG and 
fibrin in order to covalently localize factors within the matrix, these factors are then 
released via degradation of the matrix by serine proteases and matrix metalloproteinases 
(MMP) (reviewed in Zhang and Suggs, 2007, Zhang et al., 2008). Biofactor delivery of 
IGF, using a PEGylated-fibrin gel, in an Ischemia/reperfusion injury model greatly 
improved functional recovery 4 days post injury, likely due to significant continued 
release of IGF 96 hrs post injection (Hammers et al., 2012).  In a previous experiment, 
delivery of MSCs and HGF using PEGylated Fibrin gel, following myocardial infarction, 
showed increased cell survival and cell clusters within the heart, as well as improvements 
in left ventricular function (Zhang et al., 2008,).  Additionally, studies within that same 
lab have studied dual release of platelet derived growth factor bb (PDGF-BB) and 
transforming growth factor β-1 (TGF β-1), in vitro. The study showed a fast release of 
PDGF-BB and a slow release of TGF β-1(Drinnan et al., 2010). Therefore, a systematic 
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and slow release of MSC via PEGylated fibrin degradation could promote angiogenesis 
in a volumetric muscle loss model and thus increase function.  
 
Reinnervation and Vascularization of the ECM 
 Reinnervation following skeletal muscle injury plays a crucial role in the 
regenerating capabilities of the muscle. Reinnervation of new myofibers is critical in a 
volumetric muscle loss injury model in order to express mature myofiber phenotypes and 
increase functional capacity. Skeletal muscle that has been denervated continues the path 
of regeneration despite lack of innervation, but if the neuromuscular junctions fail to be 
reinnervated, atrophy and tissue necrosis ensue (Jarvinen et al., 2005).  Ensuing atrophy 
of the muscle occurs at different rates, with fast muscle fibers displaying atrophy at faster 
rates than slow muscle fibers. Atrophy is then accompanied by structural remodeling, as 
well as loss of mitochondria, actin, and myosin (Borisov et al., 2001). Furthermore, 
following denervation, myogenesis occurs through satellite activation but this process is 
haulted within five to seven months post denervation due to satellite cell depletion, a 
process that affects differentiation of muscle fibers (Borisov et al, 2005). Due to the 
adverse effects seen following denervation, it is critical that new myofibers be 
reinnervated following VML injury. Studies involving neurotization in the rat soleus 
show no change in reinnervation of native end plates as result of the location of the nerve 
implant, however an increase in ectopic to native innervation ratio is witnessed with a 
distal nerve implantation (Payne and Brushart, 1997).  Despite promising motor end plate 
formation that could aid in sustaining survival and function of myofibers, the study did 
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not determine functional capabilities of the tissue. However, when direct contact is 
formed between the nerve and a motor end plate, successful reinnervation is witnessed 
(Bixby and Van Essen, 1979).  Successful innervation of tissue and regeneration of 
nerves is dependent on glial cells known as Schwann cells. Schwann cells become 
proliferative and activated to secrete and produce cytokines and neurotrophic factors that 
play an important role in axon guidance (Shimizu et al., 2007). Following dennervation, 
reinnervation by axons is dependent on previous Schwann cell tubes, as well as newly 
formed Schwann cell processes leading to end plates, a process that is limited by 
Schwann extension (Son and Thompson, 1995, 1995b, Son et al., 1996, Love and 
Thompson, 1998). However, axonal extensions, following reinnervation, were withdrawn 
if not directly led by Schwann cell process (Kang et al., 2003). A study examining the 
role of Schwann cells and axons following neurotization of the soleus, witnessed 
Schwann cell and axon migration to the soleus from the cut end of the transplanted nerve, 
a process that occcurred regardless of concurrent migration by axons (Son and 
Thompson, 1995, 1995b).  Despite the critical role Schwann cells play in axonal 
guidance, the presence of motoneurons is also paramount to Schwann cell viability. 
Motoneurons act on terminal Schwann cells, via the secretion of glial growth factor, a 
neuregulin that activates proliferation, migration, and survival (Trachtenberg and 
Thompson, 1996, 1997, Kopp et al., 1997). Neuregulin, additionally acts on muscle by 
binding tyrosine kinase receptors of the epidermal growth factor family (Erb). The effects 
of neuregulin on myoblasts were observed following treatment of human primary 
myoblasts. Human primary myoblasts treated with neuregulin expressed increases in 
 25 
acetylcholine receptors, increases in the thrombospondin-1 gene, that regulates 
proliferation, migration, and apoptosis, as well as increases in myosin heavy chains 
associated with muscle spindle fibers (Jacobson et al., 2004).  Other studies have looked 
at the role of several neurotrophic factors on skeletal muscle regeneration and neurite 
extension. In an mdx model, muscle-derived stem cells treated with nerve growth factors 
(NGF) showed enhanced muscle regeneration, and similarly NGF treated laminin 
scaffolds showed increased dorsal root ganglia, neurite extension (Lavasani et al., 2006, 
Yu et al., 1999).  Lastly, to examine the role brain-derived neurotrophic factor (BDNF) 
plays in muscle regeneration, the effects of BDNF were observed in BDNF depleted mice 
which displayed decreased Pax 7+, satellite cell expression, as well as impaired 
regeneration, characteristics that were rescued with exogenous BDNF treatment (Clow 
and Jasmin, 2010).  These studies highlight the importance of the interaction between 
muscle, nerve and terminal Schwann cells in the maintenance of the neuromuscular 
junction.  
In a study using stem cell therapy, SK-34 muscle derived stem cells were 
implanted following injury in the mouse tibialis anterior. This study found increased 
detection of donor-derived myofibers, blood vessels, and nerves, characteristics that were 
closely associated with increased mass and function of the tissue (Tamaki et al., 2005). 
The close association between these three tissue types and function reveals a need for a 
therapy that involves increases in regeneration of myofibers and nerves, and increased 
blood vessel density within the ECM construct. A previous study looking at the role of 
neurotization by the femoral nerve in a three dimensional construct showed a 5 fold 
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improvement in function as well as blood vessel formation within the construct (Dhawan 
et al., 2007).  In a later study, within our lab, looking at the role of neurotization in a 
VML injury, it was observed that neurotization significantly increases blood vessel 
density, tissue morphology, and function following MSC treatment and peroneal nerve 
transplantation (Tierney et al, 2010, unpublished). The close association between nerves 
and blood vessels is characterized by the role Netrins, Slits, and Semaphorins have on 
both neural guidance and blood vessel navigation (Autiero et al., 2005). The increase in 
blood vessel density in the previously hypoxic ECM core following neurotization, 
displays a strong link between vascularization, innervations, and regeneration.   
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SIGNIFICANCE 
Approximately, 1.3 million men and women in the United States are on active 
duty in our armed forces according to the US Department of Defense. Musculoskeletal 
extremity injuries have been reported to comprise approximately 50% of all combat 
wounds with most being from remnants of exploding grenades and missiles (Belmont et 
al., 2010). The repercussions of such injuries are profound, often causing VML injuries, 
and subsequent functional deficits (Sarathy et al., 2011, Unpublished). In cases of 
extensive traumatic injury, amputation of the injured extremity is needed (Zouris et al. 
2006). These injuries not only can cause severe physical abnormalities, often leaving 
gaps in areas where muscle regeneration is hindered often associated impeding function, 
but emotional distress over the aesthetic unpleasantness of physical abnormalities. The 
emotional distress suffered by veterans is not limited to only military populations but 
includes civilian populations incurring traumatic injuries from surgical ablations, severe 
motor vehicle accidents, and degenerative diseases. VML injuries in soldiers cause the 
greatest number of disabilities and the greatest amount of disability benefit costs (Grogan 
and Hsu, 2011). The increasing severity of injury during combat due to IEDs and the 
subsequent emotional distress associated with functional and aesthetic impairments in 
military and civilian populations due to traumatic injury attest to the importance of 
finding better therapeutic modalities to increase muscle regeneration and function 
following severe muscular injury.  
This study aims to assess the functional recovery of major muscular injuries, such 
as those suffered in combat, degenerative disease, and by medical procedures that result 
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in a VML injury. The current study is to determine the influence of neurotization of an 
ECM and stem cell administration via PEGylated fibrin gel on muscle regeneration. 
Previous work has led to our model of using a decellularized extracellular matrix (ECM) 
as a biological scaffold to support and guide myofiber in-growth in the defect site, albeit 
some major hindrances have been seen, such as the hypoxic core seen at 42 days recovery 
time (Merritt et. al, 2010). Other studies have shown ECM degradation to promote the 
recruitment of Schwann cells to the injury site (Agrawal et al., 2009). Preliminary data 
within our lab demonstrates that biofactor delivery via PEGylated Fibrin gel significantly 
improves function and structure of the injured muscle (Hammers et al., 2012). By looking 
at neurotization, the effects of time dependent stem cell release, and extended recovery 
time we will gain a better understanding of how various therapeutic modalities can 
increase regeneration which can have a clinical impact in the treatment of civilian and 
military populations suffering from a volumetric muscle loss.  
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METHODS 
ANIMALS 
Male Sprague Dawley transgenic Rats for YFP under the S100 promoter (Wesley 
Thompson’s Laboratory, Texas A&M/ University of Texas-Austin) age 3-7 months were 
used in this study. Animals were housed on a 12 hour light/dark cycle and allowed access 
to food and water, ad-libitum. Rats were randomly assigned to 6 groups (n=5-6). Animals 
in the study were treated in compliance with the ethical guidelines Institutional Animal 
Care and Use Committee (IACUC).  
 
EXTRACELLULAR MATRIX DECELLULARIZATION 
 Extracellular matrices were isolated from donor Sprague Dawley rats and 
decellularized using a protocol from our laboratory. Donor tissue was harvested and 
placed in 4% deionized water (dH2O) for 24 hours in order to induce cell swelling and 
consequent rupture. Donor ECM was then placed in a glycerol (Fisher; Pittsburgh, PA), 
sodium dodecyl sulfate (SDS) (Sigma-Aldrich; St. Louis, MO), disodium 
ethylenediaminetetraacetate dehydrate (EDTA) (Bio-Rad Laboratories; Hercules, CA), 
and deoxycholic acid (Fisher; Pittsburgh, PA),  solution for 24 hours to prepare for 
storage and placed in the freezer or placed in a Tris base (Fisher; Pittsburgh, PA), 
Glycine (Fisher; Pittsburgh, PA), and SDS (Sigma-Aldrich; St. Louis, MO) and run on an 
electrophoresis machine. The tissues were run in the electrophoresis machine with a 
constant voltage of 15V for six hours and then placed in SDS overnight. The 
electrophoresis process was repeated until all cellular material was removed. The ECM 
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was placed in DH2O for twenty-four hours followed by placement in sterile phosphate 
buffered saline (PBS) (Invitrogen; Carlsbad, CA) over night in order to remove 
remaining SDS from the matrix. Next the ECM was placed in ethanol for four hours, 
followed by multiple rinses in PBS. Lastly, the ECM was placed in sterile PBS with 1% 
antibiotic-antimycotic (AA) (Sigma-Aldrich;St. Louis, MO)  and exposed to ultraviolet 
light for at least 12 hours. Tissue was then stored at 4˚C until ready for use in VML 
treatment.  
MSC ISOLATION AND CULTURE 
 Bone marrow was obtained via surgical removal of the femur and tibia of Sprague 
Dawley rats. The shaft of the femur and tibia were flushed with Dulbecco’s modified 
eagle’s medium (DMEM) (Invitrogen; Carlsbad, CA), 10% fetal bovine serum (FBS) 
(Invitrogen;Carlsbad, CA), and 1% AA media solution using an 18G needle. Cells were 
disaggregated via gentle pipetting then centrifuged at 1000g, at 4˚C for 5 minutes. The 
resulting pellet was resuspended in the aforementioned solution and on a culture flask 
and incubated overnight at 37˚C and 5% CO2.  After 24 hours of incubation, the non-
adherent fraction was removed, centrifuged, and replated. Cells were maintained at 37°C 
and 5% CO2 and passaged as the cells reached 70% confluency. Once cells reached 
desired confluency, cells were removed from the flask using 0.25% trypsin in 1mM 
EDTA, then centrifuged and replated. Cells were then implanted once they reached 
passages 3-7. Animals receiving MSC injections were injected 1.5-2 billion cells in 25μl 
of PBS.  
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SURGICAL PROCEDURES 
 Prior to surgery, animals were randomly placed in one of six experimental groups: 
implantation of the ECM (Saline), implantation of the ECM followed by PEG 
injection(PEG), implantation of the ECM followed by PEG and BMSC injection 
(PEGMSC), implantation of the ECM followed by relocation of the plantar nerve (N), 
implantation of the ECM followed by plantar nerve relocation and PEG injection 
(NervePEG) and implantation of the ECM followed by plantar nerve relocation followed 
by PEG and MSC injection(NERVEPEGMSC). All surgery was performed under aseptic 
conditions while rats were anesthetized using 2% Isoflurane.  
 An approximately 2.0 cm incision was made into the skin at the lateral side of the 
lower leg, parallel to the tibia. The lateral portion of the LGAS was exposed by 
separating the biceps femoris from the tibia (Figure 1A). Following isolation from the 
soleus, a metal plate was used to keep separation between the soleus and LGAS. Two #9 
scalpel blades separated by a spacer were then used for removal of an approximately 1.0 
x 1.0 cm full thickness piece of the lateral gastrocnemius (LGAS) distal to the 
neuromuscular junction (Figure 1B). The excised muscle was weighed and recorded. The 
defect area was immediately replaced with a homologous, decellularized, extracellular 
matrix (ECM) of the same dimensions and sutured with nonabsorbable 5-0 polyprolene 
(5-0 prolene; Ethicon) sutures (Figure 1C).  A modified Kessler stitch with simple 
interrupted sutures on all 3 borders was utilized to secure the ECM into the defect area 
and serve as markers for later analysis (Kragh et al. 2005). The biceps femoris was 
sutured closed using simple interrupted polyprolene sutures (5-0 prolene; Ethicon). The 
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skin was closed using a simple interrupted suture (5-0 prolene; Ethicon) with the knot 
tied underneath the skin to prevent the animal from opening the incision.  
 
NERVE RELOCATION 
 During the initial defect creation, an approximately 1.0 cm incision was made on 
the medial side of the lower leg parallel to the tibia. The medial plantar nerve was 
isolated from its lateral counterpart and surrounding tissue and was denervated as distally 
as possible. The cut nerve end was redirected through the anterior and posterior 
compartments to the defect area (Figure 1D). Perpendicularly oriented myofibers of the 
LGAS and the defected area, the nerve was secured to the ECM with one non‐absorbable 
polypropylene 9‐0 suture. Following relocation, wounds were sutured as aforementioned.  
 
PEGYLATED FIBRINOGEN PREPARATION  
 
Succinimidylglutarate bi-functional polyethylene glycol (3400Da, NOF America; 
White Plains, NY) was added to human fibrinogen (80mg/ml, in PBS pH 7.6, Sigma; St. 
Louis, MO) at a molar ratio of 10:1 and incubated at 37°C for forty-five minutes. 
PEGylated fibrinogen underwent gelation by adding an equal volume solution of 
thrombin (25U/ml in 40mM calcium chloride, Sigma; St. Louis MO). 
 
 INJECTIONS 
After seven days of recovery following initial injury, the animals were 
anesthetized using 2% isoflurane.  The original skin incision was reopened, and the 
 33 
LGAS was exposed to visualize the ECM. The ECM was injected in 4-6 locations using a 
26-gauge needle with 200μl of saline (SAL), 200μl of PEGylated fibrin (PEG), or 200μl 
of mesenchymal stem cells seeded in PEGylated fibrin (PEG+MSCs (Figure 1E). After 
injection, the wounds were sutured as aforementioned.  
 
FUNCTIONAL ANALYSIS 
 Following 56 days recovery, in situ measurements were performed on both the 
experimental and the contralateral (internal control) leg. Animals were anesthetized as 
previously mentioned. An incision approximately 2 cm long was created parallel to the 
femur in order to expose the sciatic nerve. Once isolated from connective tissue and fat 
deposition, the sciatic nerve was cut as proximal to the hip as possible. A longitudinal 
skin incision was made along the posterior portion of the lower leg from the calcaneus to 
the popliteal region. The skin was separated from the biceps femoris, and a similar 
incision was made along the biceps femoris from the calcaneus to the popliteal region. 
The biceps femoris, soleus, and plantaris were separated from the gastrocnemius. 
Following separation of the LGAS, the medial GAS was dennervated to ensure force 
production isolated to the LGAS. The calcaneus was detached and the Achilles tendon 
was attached to a dual mode servomotor muscle lever system (model 310-B, Aurora 
Scientific, ON, Canada). Electrodes were placed on the sciatic nerve, and the muscle was 
stimulated to elicit maximal isometric tetanic contractions using a stimulator (Model 
2100; A-M Systems, Carlsborg, WA). The muscle was kept wet in mineral oil and the 
temperature was maintained between 36.5°C and 37.5°C with a radiant heat lamp. The 
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muscle length was adjusted to optimal muscle length with a micrometer. Peak tetanic 
tension was stimulated at 150 Hz and the minimum voltage necessary to elicit maximal 
contraction. After each contraction, the muscle was allowed to rest for 2 minutes. Total 
force, cross sectional area, and specific tension were determined. Following termination 
of functional measures, muscles were excised, weighed, and encapsulated by OCT and 
frozen in liquid nitrogen cooled isopentane. Tissues were stored in -80˚C for future 
histological and immunohistological analysis.   
 
HISTOLOGICAL ANALYSIS 
 
 Following functional analysis, the experimental LGAS was removed, cleaned of 
external connective tissue and excess fat, weighed, and frozen in liquid nitrogen cooled 
isopentane. Series of 5 μm sections were taken perpendicular to myofiber 
orientation and within the Top, Middle, and Bottom regions of the implanted ECM 
using a Leica CM1900 cryostat microtome (Leica Microsystems; Wetzlar, 
Germany) at ‐20°C. Following sectioning slides were immediately placed in acetone for 5 
minutes.  To identify myofibers, nuclei, and collagen, Hematoxylin and eosin (Sigma-
Aldrich; St. Louis, MO) staining was performed. 
 
IMMUNOHISTOCHEMISTRY ANALYSIS  
 In preparation for immunofluorescent identification, sections were placed in 
acetone for 10 minutes, followed by 3- 5 minute washes of PBS.  Sections were blocked 
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with 10% normal donkey serum in PBS. All of the following materials were purchased 
from Santa Cruz Biotechnologies, Santa Cruz, CA unless otherwise stated. Sections were 
first incubated with primary antibodies, in PBS containing 5% bovine serum 
albumin (BSA), against PECAM (2:100, goat polyclonal),  rinsed with PBS 3 times,  and 
detected with a donkey anti‐goat IgG‐FITC fluorescein(1:100, λ = 495 nm), in PBS 
containing 5% bovine serum albumin (BSA). Following another 3 PBS rinses, sections 
were counterstained with Hoescht 33258 (1:1000, λ = 395 nm:AnaSpec; San Jose, CA) to 
identify nuclei. Finally, the sections were then washed with PBS three times for 5 
minutes each, before imaging.  
 
IMAGING AND ANALYSIS 
  Hematoxylin and eosin sections were visualized with a Nikon Diaphot 
microscope mounted with an Optronix Microfire digital camera. Histological 
quantification of H&E was performed on each level and within each region of the ECM 
with the 20x objective lens. Immunofluorescence was visualized with a Leica DM LB2 
fluorescence microscope, visualized under the 20x objective lens, and photographed with 
a Leica DFC340FX digital camera (Leica Microsystems; Wetzlar, Germany). 
Histological quantification and PECAM quantification were performed in each region of 
the ECM (n = 3). Myofiber cross-sectional area (CSA) and PECAM+ structures were 
measured and visualized utilizing ImageJ software. The number of PECAM-positive 
structures within each region of the ECM implant was counted to determine the number 
of blood vessels/mm2. Implant area was determined by measuring the CSA of the 
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implanted region. A vessel was only counted if its lumen was greater than 20 μm in 
diameter. 
 
STATISTICAL ANALYSIS  
 
Data are represented as mean ± SEM. Statistical analysis was performed utilizing 
ANOVA for analysis of group samples. Comparisons between data sets were performed 
utilizing Tukey’s post hoc tests where available. Significance is defined as p < 0.05. 
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RESULTS 
MORPHOLOGICAL ANALYSIS 
 The average mass of the surgically removed tissue was 307 ± 3.7 mg wet weight, 
a value that accounts for approximately 27 % of the total mass of the LGAS. No 
significant differences in defect mass between groups were witnessed.  The mass of the 
defect allowed for a sizeable area to which view myofiber regeneration. Consistent with 
previous work within our lab, the overall morphology of the LGAS was maintained in all 
groups following 56 day recovery post injury (Merritt et al., 2009). Restoration in the 
mass of the injured LGAS reached values of 81.2 ± 1.9% of the mass of the contralateral 
LGAS. However, no significant differences in injured LGAS mass recovery were seen 
between groups. 
 
FUNCTIONAL ANALYSIS  
Functional analysis at day 56 of recovery found maximal isometric tetanic force 
(PO) produced in the saline group to measure 47.3 ± 4.2% of that produced in the 
contralateral LGAS, a value substantially lower than control. No significant differences 
were seen in PO produced by the injured LGAS between the saline group and all other 
groups or in any other interactions (Figure 2). However, when PO was observed between 
nerve (60.3 ± 4.4%) and non groups (48.9 ± 2.5%) compared to contralateral, a 
significant difference was observed between the two groups (Figure 3).  
When maximal tetanic force was measured per unit of cross sectional area (CSA), 
known as Specific tension (SPo), a significant difference was seen in the Nerve+ 
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PEG+MSC group (86.3 ± 5.8% of the contralateral LGAS) in comparison to Saline (62.9 
± 5.5%), PEG (54.6 ± 3.8%), and Nerve+PEG (57.1 ± 2.8%)  groups (p < 0.05) (Figure 
2). Interestingly, although not significant, PEG only and PEG+Nerve groups decreased 
both the maximal tetanic tension and the specific tension of these groups.  
Additionally, mass of VML injury, Po, and SPo in non-nerve and nerve groups 
were compared to previous work done within our lab. A look at mass of tissue removed 
from the LGAS of the rat revealed significantly more tissue removed in this study 
compared to previous neurotization work done within this laboratory. A significant 
difference in mass between both non-nerve (305.3 ± 6.9 mg) and nerve groups (309.7 ± 
3.6 mg) compared to non-nerve (189.5 ± 5.2 mg) and nerve (177.9 ±4.2 mg) in the 
previous study (Tierney et al., 2009, unpublished) (figure 4).  Maximal tetanic tension in 
this study was significantly lower for nerve (75.1 ± 1.9%) and non-nerve groups (82.1 ± 
4.3%) in comparison to Tierney et al., nerve (88.4 ± 2.6%) and non-nerve groups (92.9 ± 
2.6%), (Figure 5).  This decrease in function was also observed when tissue cross 
sectional area was accounted for, between nerve (82.1 ± 4.3%) and non-nerve groups 
(75.1 ± 1.9%) in comparison to nerve (94.9 ± 2.5%) and non-nerve groups (88.4 ± 2.6%) 
from Tierney et al., (Figure 6). 
 
HISTOLOGY  
 Histological analysis of the defect area following 56 days of recovery 
demonstrated myofiber infiltration within the ECM. Cellular material staining by 
hematoxylin and eosin in the top, middle, and bottom regions of the ECM showed 
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cellular infiltration throughout all regions of the ECM. Myofiber cross sectional area was 
measured in the bottom (8a), middle (10a), and top (12a) of the implanted ECM. All 
regions contained small myofibers with nuclei centralized throughout the ECM. All 
groups in all regions of the ECM displayed left skewiness in cross sectional area of the 
myofibers; however, the phenotype for smaller, regenerating myofibers was slightly 
recovered in all regions by neurotization of the ECM. All groups showed dense packing 
of cellular content proximal to implantation borders where the ECM was sutured onto the 
tissue.  
 Hematoxylin and eoisn staining showed fibers in the bottom portion of the ECM 
that were both regenerating, in the process of maturing, or mature, as is evidenced by the 
location of nuclei either centrally or in the periphery of the cell (Figure 7). Visual 
analysis showed myofibers that were larger for all groups compared to the saline group 
(Figure 7).  Measurement and quantification of myofibers of average size between 4000 
μm² and 6500 μm², showed a significant difference in PEG, MSC, Nerve, and 
NervePEGMSC groups compared to Saline treatment (Figure 8B). Additionally, 
PEGMSC, NervePEG, and NervePEGMSC displayed significant difference in average 
size of the myofibers compared to both PEG and Nerve groups. Furthermore, there was a 
significant increase in average myofibers in both the MSC and NervePEG group in the 
bottom region of the ECM compared to the NervePEGMSC.  
 Visual analysis of H&E staining of the middle region of the ECM saw myofibers 
that were much smaller, less densely packed, and expressed central nucleiation (Figure 
9). Further examination of CSA of averaged sized myofibers, between 4000- 6500 μm², 
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revealed significant differences in CSA in the middle region of the PEGMSC, Nerve, and 
NervePEGMSC groups in comparison to Saline (Figure 10B). Surprisingly, the Nerve 
group was the only group to display significant differences compared to PEG and 
NervePEG groups.  
 Examination of the top region of the ECM showed myofibers that were larger in 
size and morphologically similar to uninjured tissue but continued displaying 
regenerative patterns of central nucleiation, although less frequently in the 
NervePEGMSC group (Figure 11). Quantification of cross sectional area of average 
myofibers 4000-6500μm² revealed no significant differences between groups in this 
region of the ECM.  
 
IMMUNOHISTOCHEMISTRY  
 Immunohistochemical analysis showed angiogenesis of the ECM in all regions. 
PECAM staining revealed blood vessel in all regions of the ECM, while the presence of 
central nuclei, identified by Hoechst 33258, substantiate the presence of these blood 
vessels amid regenerating myofibers in the middle region of  ECM (Figure 13). 
Quantification of blood vessels larger than 20μm in the top region revealed a significant 
difference in blood vessel density (BV/mm²) in the NervePEGMSC, Nerve, and 
NervePEG group compared to Saline (Figure 14). Additionally, a significant difference 
was also observed in NervePEGMSC compared to PEG and PEGMSC groups. 
Surprisingly however, quantification of blood vessel density in the middle region of the 
ECM showed a significant difference only in the NervePEGMSC group in comparison to 
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Saline and PEG groups (Figure 15).  Lastly, blood vessel density was shown to increase 
significantly in the NervePEGMSC group compared to Saline (Figure 16). These 
increases indicate that NervePEGMSC treatment has a direct role in increasing blood 
vessel density within all regions of the implanted ECM.  
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DISCUSSION  
 Traumatic injuries incurred during combat by military personnel and in motor 
vehicle accidents, by the civilian population are often suffered in the extremities. These 
types of injuries are characterized by substantial muscle mass loss, decreased tissue 
regeneration, and subsequent functional deficits.  Associated mental distress ensues after 
limb salvage surgeries due to the cosmetic and functional deficits that accompany such 
traumatic injuries. These injuries have been associated with significant medical costs, 
consisting of initial hospital visits and subsequent therapies to regain function, as well as 
costs associated with disability compensation. It is estimated that almost 3 billion dollars 
are spent in treatment and disability benefits for those suffering from volumetric muscle 
loss associated injuries. Therefore, it is imperative that treatments which maximize 
regeneration of myofibers and functional improvements be developed, in order to 
minimize both the medical and disability costs and the emotional distress felt by patients.  
 A volumetric muscle loss injury and subsequent ECM implantation results in 
deficient self –repair and associated and sustained functional loss even after 56 days of 
recovery, in accordance with previous work in our laboratory (Merritt et al., 2010, 
Tierney et al., 2010, Merscham-Banda et al., 2012).  This phenotype was rescued by the 
combination treatment of neurotization of the plantar nerve on the ECM and MSC 
delivery via a PEGylated Fibrin gel. The combination of treatment significantly improved 
myofiber cross sectional area and blood vessel density and specific tension in the 
implanted ECM. Improved myofiber infiltration was also witnessed in the PEGMSC 
group and all nerve groups, indicating that MSCs and nerves play a role in muscle repair. 
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However, increases in blood vessel density were only associated with nerve treatments, 
indicating a direct role of nerve on angiogenesis.  
 Although unable to fully regenerate tissue morphology and function, our ECM 
constructs had the capability of allowing cellular, myofiber, and blood vessel infiltration 
without any further treatments. The deficiencies in function and self repair are likely a 
consequence of incomplete penetration, by infiltrating myofibers. Studies have shown 
that ruptures in muscle in excess of 3mm greatly hinder the reparative capacity of 
myofibers as transected end are not able to travel long distances in order to fuse together 
(Terada et al., 2002). Increases in cellular content within the ECM primarily occurred in 
the bottom and top regions indicating possible myofiber in-growth following VML 
creation. The exact mechanism of regeneration, however, was not within the scope of this 
study. It is likely however that cellular content increases occurred due to the role of MSC 
in one of three mechanisms: de novo myofiber formation, fusion to existing infiltrating 
myofibers, or through a paracrine/autocrine signaling mechanism that recruits other cells 
and repair mechanisms. Research has shown that MSC exerts its effects via two different 
mechanisms: they first migrate from the bone marrow and incorporate into the satellite 
cell niche, under the basal lamina, in order to repopulate that stem cell population, 
followed by mobilization and engraftment following injury (LaBarge and Blau, 2002).  
Many other studies have shown incorporation into the satellite cell niche, possibly 
indicating that MSC indirectly contributes to muscle repair by satellite cell repopulation 
which then can become activated for muscle repair and nuclei donation to myofibers. 
Other research has shown that MSC engraftment occurs in vivo and that as many as 10% 
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of myofibers show MSC engraftment leading to dystrophin recovery in animal models of 
Duchenne muscular dystrophy (Gussoni et al., 1999, Nitahara-Kasahara, 2012).  
Although engraftment has been shown to occur, the values of engraftment have been 
minimal in comparison to the functional recovery seen following MSC treatment. These 
low occurrences of engraftment and increased functional recoveries have led to the belief 
that MSC must have an impact on recovery by other mechanisms (Prockop, 2003, 2009).  
It is likely that MSC act on the VML model through paracrine action to increase cellular 
content. Studies have shown that MSC can act to prevent cellular apoptosis and decrease 
fibrosis, events that increase left ventricular function following MSC treatment (Shabbir 
et al., 2009). The increases in functional recovery following MSC treatment are likely a 
role of growth factor release by MSC, among which, are VEGF, TSG-6, and IGF 
(Shabbir et al., 2009, Lee et al., 2009, Prockop, 2009).  Certainly, paracrine action of 
chemokine release, by MSC, aided in the recruitment of progenitor cells, that likely 
contributed to the increases we witnessed in cellular content of the implant.  
 Mesenchymal stem cell secretion of VEGF has been attributed to neoangiogenesis 
subcutaneously and in the VML model of injury (Al-Khaldi et al., 2003, Tierney et al., 
2009). The effects of MSCs angiogenesis is seen in a study looking at CD31+ vessels 
following exercise, an increase in CD 31+ vessel size and NG2 proteogylcan positive 
arterioles was seen within a week of injection (Huntsman et al., 2013). However, in our 
study we found that MSC worked in conjunction with nerve groups to significantly 
increase blood vessel density within our ECM construct. PEGMSC showed no significant 
increases in blood vessel density making it unlikely the cause of the increase in blood 
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vessel density. It is possible however, that MSC exerts its role in conjunction with nerve 
in order to amplify its VEGF response. Recently, it has been determined that VEGF is 
expressed in neurons and hypothesized that it may act on axonal outgrowth, as well as in 
the recruitment of undifferentiated neural progrenitors (reviewed in Autiero et al., 2005). 
Recently, research has looked at the effects of nerve growth factor (NGF) secreted by 
peripheral neurons on endothelial cells and it has been suggested that NGF acts on VEGF 
by stimulating its production. Research on the role of NGF on angiogenesis, found that 
NGF treatment alone or in concert with 6-hydroxy-dopamine (6-OHDA), a neurotoxic, 
elicited an up-regulation of VEGF in superior cervical ganglia and subsequent 
angiogenesis, an effect that was higher in combination than with NGF alone (Calza et al., 
2001). In a similar study looking at the role of NGF on angiogenesis, following ischemia, 
found that NGF blocking impaired the angiogenic response in comparison to local NGF 
supplementation, which increased the rate of perfusion recovery (Emanueli et al., 2002). 
These studies indicate that neurotization of the construct alone can elicit a strong 
angiogenic response via secretion of NGF and its role on up-regulation of VEGF. This 
falls in accordance with our results that treatments involving nerve relocation 
significantly increase blood vessel density within the tissue construct and that pairing 
neurotization with a combined treatment, in this case MSC delivery would further 
increase blood vessel density. This combined effect is especially witnessed in the middle 
and top regions of the ECM construct, where the combined treatment significantly 
increased blood vessel density. In addition, satellite cells have been witnessed to reside in 
close proximity of blood vessels, a study in which blood capillary numbers were reduced 
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by 45%, saw a decrease in more than half the mean of satellite cells (Christov et al., 
2007). This study indicates the complexity of involvement between the many factors that 
increase regeneration in the skeletal muscle. Additionally, other studies have shown that 
neuregulin-1 acts on the SC population by promoting differentiation (Hirata et al., 2007). 
It is possible that both MSC and nerve secrete growth factors that stimulate and enhance 
the secretion of VEGF to increase blood vessel density, while subsequently MSCs 
repopulate the SC which are affected by blood vessels, which then engraft onto the 
damaged tissue.  
Despite morphological regeneration and blood vessel increases observed in the 
nerve groups and in the MSC groups. Functional improvements were only observed 
following 56 days of recovery in specific tension of the combined, NervePEGMSC group 
and Nerve only group. This characteristic is likely attributed to the significant increases 
seen in blood vessel density of the ECM, coupled with significant increases in cellular 
infiltration in the middle region of the ECM in these groups. While other groups showed 
increases in myofiber infiltration within the middle region of the ECM, it is possible that 
treatments have the ability to increase cellular infiltration via chemokine secretion but 
sustained function of these new myofibers occurs only in the presence of significant 
blood vessel density. Studies have highlighted the importance of vascularization and 
innervation of newly regenerating muscle fibers to the morphological and functional 
recovery of the injured muscle (Jarvinen, M., 1976a). The possibility that blood vessel 
number aid in regeneration via their role in gas, chemokine, and other biofactor 
exchange, in treatment groups that also displayed an increase in cellular content in the 
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middle region, is highlighted by our results showing a functional increase in Nerve and 
NervePEGMSC groups. These two treatments were the only two groups that displayed 
both increased cellular content in the middle region of the ECM and increased blood 
vessel density.  
 In summary, this study reveals that the treatment of a VML injury with MSCs in a 
PEGylated Fibrin hydrogel and plantar nerve implantation significantly improves 
histological, morphological, and functional recovery over ECM implantation alone. The 
combination of neurotization of the ECM construct seeded with MSC via PEGylated 
Fibrin gel significantly improves blood vessel density, a characteristic that either 
indirectly, through its associatetion with the nerve, or directly through gas and waste 
exchange with the tissue, improves function. The exact mechanism by which the 
combined treatment aids to restore function remains unclear and was not within the scope 
of this study, however it is hypothesized that it functional improvements occur via release 
of trophic factors by the ECM, nerve, and MSCs which recruit progenitor cells. Although 
function and histology of PEGylated groups did not significantly differ from Saline 
groups, future studies could observe the role of growth factor delivery on muscle 
regeneration in the VML model. Additionally, future studies could characterize 
macrophage phenotypes within the VML model in order to establish the role of 
macrophages in tissue remodeling and regeneration following treatments. Macrophage 
characterization and time course of infiltration would likely provide great insight to VML 
treatments, due to the role distinct macrophage populations play in hampering or 
increasing regeneration. Thus this work and future studies could play a beneficial role in 
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finding better clinical applications that would enhance tissue regeneration and function in 
military and civilian populations.  
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Figure 1: Schematic diagram of surgical procedures in VML injury model. A.) 
Uninjured LGAS. B.) Creation of 1x1cm VML injury. C.) Repair of injury with ECM 
using a modified Kessler stitch. D.) Neurotization procedure using Plantar nerve. E.) 
Injection of Saline, PEG, or PEG + MSC, 7 days post injury.  
 
A. B. 
D. E. 
C. 
 50 
 
Figure 2: Functional recovery in LGAS. Tetanic tension (Po) and specific tension 
(SPo) following 56 days of recovery of the LGAS relative to the contralateral limb. ♯ 
indicates significance from SAL group. * indicates significance from PEG group. β 
indicates significance from NervePEG group. Significance is set at p < 0.05. 
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Figure 3: Tetanic Tension in LGAS. Tetanic tension (Po) following 56 days of recovery 
of the LGAS relative to the contralateral limb for Non Nerve and Nerve groups. ǂ 
indicates significance from Non Nerve group. Significance is set at p < 0.05. 
 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Non Nerve groups Nerve groups
%
 o
f 
C
o
n
tr
al
at
er
al
 L
eg
, P
o
ǂ
 52 
 
Figure 4: Mass of VML creation. Mass of injury created in LGAS of Tierney et al, 
2009 and current study. ǂ indicates significance from Tierney et al, 2009 Non Nerve 
group.  * indicates significance from Tierney et al, 2009 Nerve group. Significance is set 
at p < 0.05. 
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Figure 5: Tetanic Tension Comparison. Tetanic tension (Po) following recovery of the 
LGAS after 56 days, relative to the contralateral limb for Non Nerve and Nerve groups, 
within the current study and in Tierney et al, 2009. ǂ indicates significance from Tierney 
et al, 2009 Non Nerve group.  * indicates significance from Tierney et al, 2009 Nerve 
group. Significance is set at p < 0.05. 
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Figure 6: Specific Tension Comparison. Specific tension (SPo) following recovery of 
the LGAS relative to the contralateral limb for Non Nerve and Nerve groups in the 
current study compared to Tierney et al, 2009. ǂ indicates significance from Tierney et al, 
2009 Non Nerve group.  * indicates significance from Tierney et al, 2009 Nerve group. 
Significance is set at p < 0.05. 
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Figure 7: Hematoxylin and eosin staining. Myofiber infiltration with H& E staining in 
bottom region of ECM implant taken with 20x objective lens. (A.) SAL group (B.) PEG 
group (C.) PEGMSC group (D.) NERVE group (E.) NERVEMSC group (F.) 
NERVEPEGMSC group Scale bar = 100 μm. 
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Figure 8: Cross sectional area of bottom region of VML. CSA was determined 
through Hematoxylin & Eosin staining. A.) Fiber size distribution was determined in the 
bottom region of the ECM. B.) Proportion of average fibers between 4000 μm² and 6500 
μm² compared to total fibers. # denotes significant difference compared to ECM. * 
Denotes significant difference compared to PEG only. ǂ denotes significance compared to 
MSC group. α denotes significance compared to Nerve only. β denotes significance 
compared to Nerve+ PEG. Significance is set at p < 0.05. 
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Figure 9: Hematoxylin and eosin staining. Myofiber infiltration with H& E staining in 
middle region of ECM implant taken with 20x objective lens. (A.) SAL group (B.) PEG 
group (C.) PEGMSC group (D.) NERVE group (E.) NERVEMSC group (F.) 
NERVEPEGMSC group Scale bar = 100 μm. 
 
 58 
 
 
Figure 10: Cross sectional area of middle region of VML. CSA was determined 
through Hematoxylin & Eosin staining. A.) Fiber size distribution was determined in the 
middle region of the ECM. B.) Proportion of average fibers between 4000 μm² and 6500 
μm² compared to total fibers. Muscle fiber CSA was compared among all treatment 
groups.  # denotes significant difference compared to ECM. * Denotes significant 
difference compared to PEG. β denotes significance compared to Nerve+ PEG. 
Significance is set at p < 0.05. 
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Figure 11: Hematoxylin and eosin staining. Myofiber infiltration with H& E staining in 
top portion of ECM implant taken with 20x objective lens. (A.) SAL group (B.) PEG 
group (C.) PEGMSC group (D.) NERVE group (E.) NERVEMSC group (F.) 
NERVEPEGMSC group Scale bar = 100 μm. 
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Figure 12: Cross sectional area of Top region of VML. CSA was determined through 
Hematoxylin & Eosin staining. A.) Fiber size distribution was determined in the top 
region of the ECM. B.) Percentage of average fibers between 4000 μm² and 6500 μm² 
compared to total fibers. Muscle fiber CSA was compared among all treatment groups.  
Significance is set at p < 0.05. 
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Figure 13: PECAM staining. Angionesis observed via PECAM staining in mid portion 
of ECM implant, image taken with 20x objective lens. Images taken of blood vessels ≥ 
20μm. (A.) SAL group (B.) PEG group (C.) PEGMSC group (D.) NERVE group (E.) 
NERVEMSC group (F.) NERVEPEGMSC group Scale bar = 100 μm. 
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Figure 14: Blood Vessel Density in Top region of VML. Blood vessel density was 
determined through PECAM staining. Only blood vessels ≥ 20μm were counted. # 
denotes significant difference compared to ECM. * Denotes significant difference 
compared to PEG only group. ǂ denotes significance compared to MSC group. 
Significance is set at p < 0.05. 
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Figure 15: Blood Vessel Density in Middle region of VML. Blood vessel density was 
determined through PECAM staining. Only blood vessels ≥ 20μm were counted. # 
denotes significant difference compared to ECM. * Denotes significant difference 
compared to PEG only group. Significance is set at p < 0.05. 
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Figure 16: Blood Vessel Density in Bottom region of VML. Blood vessel density was 
determined through PECAM staining. Only blood vessels ≥ 20μm were counted. # 
denotes significant difference compared to ECM. Significance is set at p < 0.05. 
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APPENDIX A: EXPANDED METHODS  
I. EXTRACELLULAR MATRIX DECELLULARIZATION:  
1. Place separated gastrocnemius muscles in a 50ml conical tube with deionized (DI) 
water at 4°C for 24 hours.  
2. Place muscle in electrophoresis tank  
3. Fill electrophoresis tank with Tris-Glycine solution  
4. Run electrophoresis machine at 15V for 6 hours.  
5. Remove tissue after 6 hours running and place in SDS overnight 
6. Repeat steps 2-6, until ECM is completely decellularized. 
7. Rinse ECM in DI water for 72 hours.  
8. Place the ECM in 70% ethanol for 4 hours.  
9. Remove ethanol and place ECM in sterile PBS with 1% AA and expose to ultraviolet 
(UV) light for a minimum of 12 hours.  
10. Store in PBS with 1%AA at 4°C until ready for implantation.  
11. ECM not immediately decellularized are placed in glycerol solution for 24 hrs at 4°C.  
12. Then transferred to the freezer until ready for decellularization.  
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II. VOLUMETRIC MUSCLE LOSS & REPAIR  
1. Autoclave all instruments that will come into contact with the animal, including bench 
liners. Observations should be made every 15 minutes for the duration of the surgical 
procedure.  
2. Weigh and anesthetize the animal until absence of withdraw reflex is seen. 
3. Give analgesic, .01ml/g 
4. Shave the hindlimb in which the defect will be created.  
5. Using a scalpel cut a two-centimeter incision on the lateral side of the lower leg, 
parallel with the tibia.  
6. Separate the biceps femoris from the tibia to expose the LGAS.  
7. Separate the soleus from the LGAS and place a small aluminum foil plate between the 
soleus and LGAS to prevent injury to the soleus upon defect creation.  
8. Using two scalpel blades separated by a 1cm spacer, create the full-thickness defect 
distal to the neuromuscular junction and in line with the tibial tuberosity.  
9. Cut the medial edge of the defect using a pair of fine surgical scissors, and weigh the 
excised tissue.  
10. Cut a piece of the extracellular matrix roughly the same dimensions as the tissue 
excised and implant it into the area of defect.  
11. Using a modified Kessler stitch, suture the ECM with non-absorbable 5-0 polyprolene 
sutures.  
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12. Stitch simple sutures at the proximal, distal, and medial portions of the ECM to mark 
the edges of the ECM for later analyses.  
13. Close the wound by suturing the biceps femoris utilizing simple interrupted stitches. 
Suture the skin incision using simple interrupted sutures with the knot tied underneath the 
skin to ensure the animal does not open the wound.  
14. Return animal to cage and monitor until animal has regained consciousness and 
mobility.  
15. Monitor animal for the next 48 hrs.  
16. Give subcutaneous analgesic .01ml/g at 12 hrs, 24, and 48 post surgery.  
 68 
III. A. BONE MARROW DERIVED MESENCHYMAL STEM CELL ISOLATION:  
1. Prior to bone marrow isolation, sterilize all instruments and warm two 50 ml conical 
tubes containing media to 37°C in the water bath.  
2. Fill two sterile petri dishes with sterile DPBS.  
3. Anesthetize the animal and shave the hindlimbs.  
4. Surgically remove both femurs and tibias. Remove as much muscle and connective 
tissue as possible, and place bones in one of the DPBS filled petri dishes.  
5. Allow bones to sit in DPBS for a few minutes. This will help in further removal of any 
remaining tissue on the bones.  
6. After cleaning the bones a second time, cut the epiphyses of the bones and place in 
second DPBS filled petri dish. Transport dish to the tissue culture hood.  
7. Place one of the media tubes from the water bath under the hood.  
8. Obtain four sterile 50 ml conical tubes (one for each bone) and place under the hood.  
9. Using an 18-G needle attached to a 3ml syringe, draw up some media and flush out the 
bone marrow of each bone. Use a total of 10 ml of media per bone, for each tube.  
10. Mechanically disrupt bone marrow clumps by drawing the bone marrow containing 
media up and down using a series of smaller syringes (16G, 18G, 21G).  
11. Transfer media in each of the 50 ml tubes to 15 ml conical tubes (one for each bone).  
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12. Centrifuge the tube at 1000 x g for 5 minutes at 4°C.  
13. Remove the supernatant and resuspend the pellet in 3 ml of media.  
14. Obtain four 25 cm2 tissue culture flasks and plate the cells (one tube per flask). Add 7 
ml of media to each flask, for a total of 10 ml of media per flask.  
15. Place flasks in incubator set at 37°C and 5% CO2 for 24 hours.  
16. Remove media (this is the non-adherent fraction) from flasks and place in four sterile 
15 ml conical tubes. Centrifuge and plate as described above.  
17. Rinse the first set of flasks at least twice with DPBS to remove remaining RBCs and 
debris.  
18. Change media and rinse the flasks with DPBS for the next two consecutive days.  
19. After this time period, change the media every 2-3 days until the cells have reached 
~80% confluency and the cells must be split.  
IV. MSC CULTURE:  
Media Preparation:  
1. Control media is made up of 90% Dulbecco’s Modified Eagles Medium (DMEM) + 
10% Fetal Bovine Serum (FBS) + 1% Antibiotic/Antimycotic (AA)  
2. In a sterile 50 ml conical tube, add 45 ml of DMEM + 5 ml FBS + 1 ml AA.  
3. Store media at 2-8°C.  
4. Prior to use, warm media in 37°C water bath for at least 15 minutes.  
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Changing Media:  
1. Cells should be monitored microscopically daily, and confluency should be noted.  
2. Media should be changed every 2-4 days.  
3. To change media, aspirate old media, rinse flask twice with DPBS and replace with 10 
ml of fresh media.  
4. When cells have reached ~80% confluency, they must be trysinized.  
 
Passaging Cells:  
1. Once cells have reached ~80% confluency, remove media from flasks and rinse twice 
with DPBS.  
2. Replace DPBS with 3 ml 0.25% Trypsin/EDTA and place in incubator for three 
minutes.  
3. Remove flasks from incubator and tap flasks against the side of a table to induce 
detachment of cells. Use the microscope to verify cells are detached.  
4. Remove cell suspension from flasks and place in sterile 15 ml conical tube (one tube 
per flask).  
5. Rinse flask with DPBS to obtain remaining cells, and place DPBS in appropriate tube.  
6. Centrifuge tubes at 1000 x g for five minutes at 4°C.  
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7. Remove supernatant from tubes and resuspend in 3 ml of fresh media.  
8. Split each tube into desired number of flasks. Prior to adding cell suspension to flasks, 
place 7 ml of media into each flask, for a total of 10 ml of media per flask. 
 
9. Place flasks in incubator at 37˚C and 5% CO2.  
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Cryopreservation: 
1. In the event that cells must be frozen for future use instead of passaged, carry out steps 
1-6 as described in the previous section.  
2. After centrifugation, resuspend cells in 1ml of freezing medium.  
3. Place cell suspension in a 2 ml cryotube and place in -80°C freezer for two days, after 
which, tube can be transferred to liquid nitrogen.  
 
Thawing:  
1. Obtain cells from liquid nitrogen storage and place 2 ml cryotube in 37°C water bath 
until a small amount of ice remains.  
2. Place the 1 ml suspension in a sterile 15 ml conical tube, rinse cryotube with 1 ml 
DPBS, and place DPBS in conical tube.  
3. Slowly pipette 4 ml of freshly warmed media into the conical tube, and gently pipette 
media up and down.  
4. Centrifuge at 1000 x g for 5 minutes at 4°C.  
5. Remove supernatant from tubes and resuspend in 3 ml of fresh media.  
6. Split each tube into desired number of flasks. Prior to adding cell suspension to flasks, 
place 7 ml of media into each flask, for a total of 10 ml of media per flask.  
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7. Place flasks in incubator set at 37°C and 5% CO2. 
  
V. IN SITU FUNCTIONAL ANALYSIS  
1. Weigh and anesthetize the animal, and shave hindlimbs of both legs.  
2. Create a 2 cm skin incision parallel to the femur to expose the biceps femoris.  
3. Locate the origin of the biceps femoris and separate the connective tissue with forceps 
until they go through the biceps femoris.  
4. Separate the tissue using hemostats until you can locate the sciatic nerve.  
5. Cut the biceps femoris along the femur towards the hip.  
6. Isolate the sciatic nerve from surrounding musculature and cut the nerve as close to the 
hip as possible.  
7. Remove any remaining tissue from the sciatic nerve and tuck it back into place.  
8. Make an incision along the midline of posterior portion of the lower limb from the 
calcaneus to the popliteal region.  
9. Separate the skin from the biceps femoris, and cut the biceps femoris similarly to the 
skin to expose the LGAS.  
10. Isolate the gastrocnemius from the biceps femoris.  
11. Dennervate the MGAS. This will ensure force will be measured only in the LGAS.  
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12. Cut the calcaneus so that the distal portion of the gastrocnemius and Achilles tendon 
are still attached.  
13. Separate the soleus and plantaris from the GAS by cutting the distal insertions.  
14. Using the calcaneus to hold it in place, tie the Achilles tendon to the muscle lever arm 
of the dual-mode servometer.  
15. To stimulate the LGAS, place electrodes connected to a muscle stimulator (Model 
2100) on the sciatic nerve.  
16. Keep the muscle warm with a radiant heat lamp, and occasionally moisten the muscle 
and nerve with mineral oil. 
17. Using a micrometer, find the muscle’s optimal length.  
18. Stimulate the LGAS at 150Hz to determine peak tetanic tension. Allow two minutes 
of rest between contractions.  
19. After functional analysis is completed, remove the gastrocnemius and other tissues of 
interest.  
20. Carefully separate the MGAS and LGAS.  
21. Weigh muscles and measure the length of the LGAS.  
22. Freeze muscles in liquid nitrogen cooled isopentane and store in -80°C freezer.  
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VI. HEMATOXYLIN & EOSIN STAINING:  
Hematoxylin & Eosin staining is one of the most used stains in histology to examine 
tissue morphology. Hematoxylin stains nucleic acids a deep blue-purplish color. Eosin 
stains cytoplasm, red blood cells and skeletal muscle fiber pink.  
1. Using the tall Coplin jars, immerse slides in Harris Hematoxylin for five minutes.  
*Pour out the solution and gently rinse in tap water until water runs clear.  
2. Immerse slides in Eosin for two minutes.  
* Pour out the solution and gently rinse in tap water until water runs clear.  
3. Immerse slides in 70% ethanol for several seconds. Ethanol will dehydrate the section 
and remove excess eosin.  
4. Pour out ethanol and immerse slides in 100% ethanol for several seconds.  
5. Under the fume hood, immerse slides in Xylene for several seconds. Xylene will make 
the tissue hydrophobic so a coverslip can be applied with a resin in solvent (Permount).  
6. Remove the slides from Xylene and allow slides to dry for 30 minutes in the hood.  
7. Apply a coverslip using a few drops of Permount.  
 
VII. PECAM AND HOECHST 33258 STAINING:  
Immunofluorescence allows the visualization of specific proteins, through the binding of 
an antibody to the protein of interest; a secondary antibody is then applied that is 
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chemically conjugated to a fluorescent dye. Under specific filters the protein of interest 
can be visualized.  
1. Immerse slides in cold Acetone for 10 minutes. 
2. Immediately, rinse slides with PBS 3 times for 5 minutes.  
3. Place slides in humid box. Using a barrier pen, draw circles around specimen in order 
to prevent solutions from running of the slide. 
4. Immerse slides in 10% normal serum in PBS for 20 minutes. 
5. Rinse slides with PBS 3 times for 5 minutes. 
6. Incubate tissue slides in PECAM-1, primary antibody (2:100), in the 4˚C refrigerator 
for 1 hour.  
7. Rinse slides with PBS 3 times for 5 minutes.  
8. Incubate tissue in 2˚ anti-body, (anti-goat conjugated to fitc) at room temperature for 
45 minutes. (1:100) 
9. Rinse with PBS 3 times for 5 minutes.  
10. Incubate sections with Hoechst 33258 (1:1000) for 15 min. 
11. Rinse with PBS 3 times for 5 minutes.  
12. Image immediately following PBS washes.   
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APPENDIX B: RAW DATA 
 
MASS AND FORCEMEASUREMENT DATA 
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CROSS SECTIONAL AREA  
Bottom 
MYOFIBER SIZE ECM PEG PEG+MSC Nerve Nerve+PEG Nerve+PEG+MSC 
500 24.90 19.77 18.08 32.61 15.14 15.73 
1000 27.40 28.40 14.62 25.57 14.85 18.96 
1500 15.53 14.04 7.45 11.33 6.35 10.92 
2000 8.74 6.23 4.68 6.11 5.77 7.05 
2500 4.55 3.07 4.82 4.31 4.22 4.76 
3000 2.47 2.77 5.36 3.62 3.83 3.32 
3500 2.04 2.60 6.19 3.60 3.10 2.68 
4000 1.12 2.98 5.07 2.75 4.12 3.07 
4500 1.55 2.75 4.38 2.64 4.22 2.92 
5000 0.65 2.36 4.38 1.74 3.68 2.53 
5500 0.92 2.77 3.46 1.45 3.88 3.27 
6000 1.08 2.80 4.53 1.13 5.09 3.07 
6500 0.82 2.13 3.70 0.97 4.41 2.73 
7000 0.65 1.84 2.19 0.79 4.36 2.33 
7500 0.95 1.22 2.09 0.45 4.07 3.32 
>7500 6.56 4.18 8.92 0.84 12.81 13.25 
% OF 
AVERAGE:  6.16 15.82 25.54 10.72 25.43 17.62 
SEM:  1.25 1.29 2.38 3.08 2.00 1.09 
 
Middle 
MYOFIBER SIZE ECM PEG PEG+MSC Nerve Nerve+PEG Nerve+PEG+MSC 
500 26.51 25.85 15.86 14.70 16.56 15.14 
1000 33.58 29.33 26.09 16.00 27.38 22.58 
1500 17.23 15.82 15.29 13.28 16.82 17.24 
2000 7.39 8.23 8.91 8.78 10.01 11.95 
2500 4.38 4.41 5.66 8.67 6.20 7.05 
3000 2.96 3.09 3.99 7.13 4.53 4.34 
3500 1.64 2.91 3.27 6.34 3.98 3.57 
4000 1.25 2.15 2.74 3.62 2.68 3.66 
4500 0.99 1.63 2.45 3.90 1.96 2.24 
5000 0.64 1.45 2.56 2.91 1.47 2.15 
5500 0.74 1.16 1.96 2.99 1.58 1.71 
6000 0.51 0.80 1.78 2.08 1.18 1.44 
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6500 0.39 0.64 0.99 1.77 0.69 1.06 
7000 0.53 0.57 1.28 1.22 0.69 0.97 
7500 0.18 0.38 1.24 1.18 0.60 0.79 
>7500 0.99 1.48 5.84 5.36 3.60 4.04 
% OF 
AVERAGE:  4.54 7.87 12.51 17.30 9.58 12.28 
SEM:  1.30 2.27 2.64 3.39 2.78 3.69 
 
Top 
 
MYOFIBER 
SIZE ECM PEG PEG+MSC Nerve Nerve+PEG Nerve+PEG+MSC 
500 11.74 16.15 8.01 14.02 21.49 13.81 
1000 19.29 17.00 18.31 18.14 19.60 17.84 
1500 14.69 11.50 13.16 12.95 10.93 11.52 
2000 10.79 9.34 8.49 10.34 8.16 8.78 
2500 8.12 7.86 5.30 7.17 6.07 6.40 
3000 6.87 5.66 5.20 6.55 4.35 5.03 
3500 4.70 5.03 3.92 5.15 4.45 4.91 
4000 3.75 3.59 3.29 3.42 4.35 4.14 
4500 2.91 4.06 3.07 3.31 3.71 5.23 
5000 2.87 2.45 2.86 3.23 3.34 4.02 
5500 2.23 2.41 3.34 2.28 2.42 3.10 
6000 1.92 1.77 2.81 1.58 1.61 1.89 
6500 2.20 1.43 2.86 1.65 1.78 1.77 
7000 1.15 1.69 2.38 1.54 1.85 2.05 
7500 1.42 1.52 2.33 1.32 1.11 1.57 
>7500 5.28 8.46 14.59 7.28 4.69 7.85 
% Average : 15.91 15.73 18.25 15.49 17.24 20.18 
SEM:  2.73 4.166 0.9462 3.47 4.49 5.57 
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BLOOD VESSEL DENSITY  
  
Total 
Defect 
Count 
  
Bold Vessel Density 
(BV/mm²) 
 
Saline 
ECM 
Region 
     Animal Region within Region Top  Middle  Botom Top Middle  Bottom 
103 Top 4 5 2 6.11 6.67 8 
 
Middle 3 4 6 
   
 
Bottom  4 3 4 
   101 Top 3 6 6 4.44 9.44 11.33 
 
Middle 2 6 4 
   
 
Bottom  3 5 7 
   106 Top 5 5 4 7.22 6.11 11.33 
 
Middle 3 3 6 
   
 
Bottom  5 3 7 
   
    
Average:  5.93 7.40 10.22 
    
SEM:  0.81 1.03 1.11 
        206 Top 4 5 10 11.11 8.33 17.33 
 
Middle 7 5 7 
   
 
Bottom  9 5 9 
   203 Top 3 6 8 10.56 9.44 16 
 
Middle 6 6 9 
   
 
Bottom  10 5 7 
   
    
Average:  10.83 8.89 16.67 
    
SEM:  0.28 0.56 0.67 
301 Top 6 4 10 10 11.67 12.67 
 
Middle 6 10 6 
   
 
Bottom  6 7 3 
   302 Top 5 9 10 9.44 12.22 13.33 
 
Middle 6 7 6 
   
 
Bottom  6 6 4 
   304 Top 5 8 7 13.33 12.78 16.67 
 
Middle 9 8 9 
   
 
Bottom  10 9 9 
   
    
Average:  10.93 12.22 14.22 
    
SEM:  1.21 0.32 1.24 
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402 Top 14 16 9 15.56 22.22 15.33 
 
Middle 6 15 6 
   
 
Bottom  8 9 8 
   403 Top 11 5 3 14.44 8.33 9.33 
 
Middle 10 6 5 
   
 
Bottom  5 4 6 
   407 Top 5 11 6 9.44 16.67 10 
 
Middle 6 12 2 
   
 
Bottom  6 7 7 
   
    
Average:  13.14 15.74 11.56 
    
SEM:  1.87 4.03 1.89 
500 Top 8 8 12 17.78 16.67 24 
 
Middle 12 10 10 
   
 
Bottom  12 12 14 
   503 Top 7 8 8 11.67 11.67 14 
 
Middle 8 6 8 
   
 
Bottom  6 7 5 
   
    
Average:  9.81 9.44 12.67 
    
SEM:  1.03 2.76 4.07 
602 Top 7 14 9 17.78 17.78 14.67 
 
Middle 14 9 6 
   
 
Bottom  11 9 7 
   603 Top 11 15 14 21.12 27.22 25.33 
 
Middle 12 19 10 
   
 
Bottom  15 15 14 
   604 Top 14 14 12 18.33 21.11 28 
 
Middle 7 12 16 
   
 
Bottom  12 12 14 
   
    
Average:  19.07 22.04 22.67 
    
SEM:  1.19 1.52 1.45 
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